Antheia

Biotechnology · Menlo Park, CA · Founded 2013 · Privately Held (backing)

Operator of a biotechnology company intended to develop plant-inspired medicines. Antheia is based in Menlo Park, CA and was founded in 2013. Its last reported valuation was $240 million in Jun 2021. It has raised $176 million across 5 recorded rounds; the latest was an $80 million Series C in Jan 2026.

Last reported valuation
$240.0M
Oct 2026
Priced at
—
Total raised
$176.2M
Last round
Later Stage VC (Series C)
Jan 2026
What is Antheia worth?
$240.0Mlast reported valuation · Oct 2026

Antheia's last reported valuation, Jun 2021. Nothing priced has surfaced since.

Free account
More of Antheia with a free account
  • ·The complete investor list: 23 names
  • ·Watch Antheia: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Antheia funding history

5 rounds
DateRoundRaisedPost-money
Jan 2026Later Stage VC (Series C)$80.0M▮
Jun 2021Later Stage VC (Series B)$73.0M▮
Aug 2018Early Stage VC$9.2M▮
May 2017Early Stage VC$6.2M▮
Mar 2015Seed Round$2.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Antheia valuation

Antheia's last reported valuation was $240 million in Jun 2021. No priced round, secondary trade or fund mark has surfaced since.

How much has Antheia raised?

Antheia has raised $176 million across 5 recorded rounds since 2015. The largest was a $9.2 million early-stage round in Aug 2018; the most recent was an $80 million Series C in Jan 2026.

Antheia has filed 3 Form Ds with the SEC since 2015, most recently in Sep 2018 ($9.2 million sold to 5 investors).

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: Ansa Biotechnologies ($269 million), Ambros Therapeutics ($250 million) and Gameto ($243 million).

How Antheia's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Antheia, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →

Frequently asked about Antheia

What is Antheia worth?
Antheia is valued at $240.0M as of Oct 2026. Antheia's last reported valuation, Jun 2021. Nothing priced has surfaced since.
How much has Antheia raised?
Antheia has raised $176.2M in total funding across 5 recorded rounds.
When did Antheia last raise?
Antheia last raised in Jan 2026 (Later Stage VC (Series C)), raising $80.0M.